- Home
- SLRC vs CVAC Comparison
SLRC vs CVAC Comparison
Compare SLRC & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLRC
- CVAC
- Stock Information
- Founded
- SLRC 2007
- CVAC 2000
- Country
- SLRC United States
- CVAC Germany
- Employees
- SLRC N/A
- CVAC N/A
- Industry
- SLRC Finance/Investors Services
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- SLRC Finance
- CVAC Health Care
- Exchange
- SLRC Nasdaq
- CVAC Nasdaq
- Market Cap
- SLRC 889.2M
- CVAC 764.4M
- IPO Year
- SLRC 2010
- CVAC 2020
- Fundamental
- Price
- SLRC $16.76
- CVAC $4.47
- Analyst Decision
- SLRC Hold
- CVAC Strong Buy
- Analyst Count
- SLRC 6
- CVAC 2
- Target Price
- SLRC $15.79
- CVAC $14.00
- AVG Volume (30 Days)
- SLRC 137.9K
- CVAC 779.9K
- Earning Date
- SLRC 05-07-2025
- CVAC 05-20-2025
- Dividend Yield
- SLRC 9.79%
- CVAC N/A
- EPS Growth
- SLRC N/A
- CVAC N/A
- EPS
- SLRC 1.61
- CVAC 0.87
- Revenue
- SLRC $227,510,000.00
- CVAC $566,039,775.00
- Revenue This Year
- SLRC N/A
- CVAC N/A
- Revenue Next Year
- SLRC N/A
- CVAC $37.79
- P/E Ratio
- SLRC $10.41
- CVAC $5.16
- Revenue Growth
- SLRC N/A
- CVAC 787.60
- 52 Week Low
- SLRC $13.64
- CVAC $2.37
- 52 Week High
- SLRC $17.94
- CVAC $5.28
- Technical
- Relative Strength Index (RSI)
- SLRC 61.92
- CVAC 65.61
- Support Level
- SLRC $16.21
- CVAC $3.35
- Resistance Level
- SLRC $16.80
- CVAC $4.80
- Average True Range (ATR)
- SLRC 0.24
- CVAC 0.30
- MACD
- SLRC 0.05
- CVAC 0.07
- Stochastic Oscillator
- SLRC 91.28
- CVAC 77.51
About SLRC SLR Investment Corp.
SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. It invests majorly in leveraged middle-market companies in the form of senior secured loans, financing leases and to a lesser extent, unsecured loans and equity securities.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.